## Phylogeny  
Human NTRK3 (TrkC) is classified within the Tyrosine Kinase (TK) group, Receptor Tyrosine Kinase (RTK) family, NTRK subfamily (bertrand2017crystalstructuresof pages 1-5).  
The kinase domain shares 71.9–78.3 % sequence identity with its paralogues TrkA and TrkB, with TrkB being the closest homologue (bertrand2017crystalstructuresof pages 1-5).  
Trk receptors show higher overall homology to the insulin-receptor branch than to other RTK clades (bertrand2017crystalstructuresof pages 1-5).  
Orthologous genes have been documented in mouse, where targeted deletion leads to proprioceptive and cardiac defects (barbacid1994thetrkfamily pages 1-2).  
An evolutionary conserved Trk-like receptor is present in the snail Lymnaea stagnalis, illustrating conservation from invertebrates to vertebrates (wiesmann2001nervegrowthfactor pages 4-6).  

## Reaction Catalyzed  
Protein-L-tyrosine + ATP ⇌ Protein-L-tyrosine-phosphate + ADP (wai1999molecularcharacterizationof pages 28-33).  

## Cofactor Requirements  
Catalytic activity depends on ATP binding and divalent metal ions such as Mg²⁺ or Mn²⁺, as typical for receptor tyrosine kinases (bertrand2017crystalstructuresof pages 1-5).  

## Substrate Specificity  
A universal consensus motif has not been defined for NTRK3; specificity is primarily inferred from its autophosphorylation pattern (wai1999molecularcharacterizationof pages 28-33).  
Documented autophosphorylation sites include Tyr516 in the juxtamembrane region and Tyr705, Tyr709, Tyr710 within the activation loop, together with Tyr820 in the C-lobe (wai1999molecularcharacterizationof pages 28-33).  
Phosphorylation of the activation-loop tyrosines is essential for full catalytic competence of the receptor (cunningham1997autophosphorylationofactivation pages 11-12).  

## Structure  
TrkC is organised into an N-terminal extracellular region containing a cysteine-rich segment, leucine-rich repeat domain 2, and two immunoglobulin-like domains 4 and 5 that mediate high-affinity NT-3 binding (wiesmann2001nervegrowthfactor pages 4-6).  
This is followed by a single transmembrane helix, a juxtamembrane KFG motif, and an intracellular kinase domain harbouring a variable kinase-insert domain (barbacid1994thetrkfamily pages 1-2, bertrand2017crystalstructuresof pages 5-9).  
X-ray structures of the kinase domain have been solved in complex with inhibitors, e.g. PDB 3V5Q and PDB 6KZC, both adopting an inactive DFG-out conformation (bertrand2012thecrystalstructures pages 2-5, somwar2020ntrkkinasedomain pages 11-11).  
No apo (ligand-free) crystal structure of the TrkC kinase domain is currently available (bertrand2017crystalstructuresof pages 5-9).  
The gatekeeper residue is a bulky phenylalanine that stacks against the DFG phenylalanine, occluding the hydrophobic back pocket (bertrand2012thecrystalstructures pages 2-5).  
The αC-helix is rotated outward in the inactive state, disrupting the conserved Lys-Glu salt bridge, whereas the hydrophobic regulatory spine is aligned only in modelled active conformations (bertrand2017crystalstructuresof pages 15-18).  
The kinase-insert domain is unresolved in existing structures and differs in sequence and length among Trk paralogues, representing a potential isoform-selective element (bertrand2017crystalstructuresof pages 15-18).  

## Regulation  
Ligand binding of neurotrophin-3 to the extracellular domains induces receptor homodimerisation and trans-autophosphorylation of intracellular tyrosines (bertrand2017crystalstructuresof pages 1-5, wai1999molecularcharacterizationof pages 28-33).  
Autophosphorylation at Tyr516 creates a docking site for SHC and the p85 subunit of PI3K, while phosphorylation at Tyr705, Tyr709 and Tyr710 within the activation loop is required for catalytic activation, and Tyr820 recruits PLCγ (wai1999molecularcharacterizationof pages 28-33).  
Negative feedback is mediated by Cbl family E3 ubiquitin ligases, which bind phosphorylated TrkC and promote its ubiquitination and lysosomal degradation (tang2022negativeregulationof pages 1-2).  
An alternatively spliced isoform containing a 14-residue insert lacks catalytic activity and functions as an endogenous dominant-negative regulator (wai1999molecularcharacterizationof pages 28-33).  
Conformational switching between DFG-in (active) and DFG-out (inactive) states, influenced by nucleotide or inhibitor binding, further modulates kinase activity (bertrand2017crystalstructuresof pages 9-15).  

## Function  
TrkC is prominently expressed in central and peripheral nervous system tissues and plays critical roles in neuronal survival, differentiation and synaptic plasticity (barbacid1994thetrkfamily pages 1-2, bertrand2017crystalstructuresof pages 1-5).  
It also contributes to cardiac development, as evidenced by phenotypes in knockout mice (barbacid1994thetrkfamily pages 1-2).  
Upon NT-3 binding, the receptor activates the RAS/ERK, PI3K/AKT and PLCγ pathways via recruitment of adaptor proteins such as SHC, GRB2/SOS, PI3K-p85 and PLCγ (wai1999molecularcharacterizationof pages 28-33, jiang2021developmentofsmallmolecule pages 6-9).  
Time-resolved phosphoproteomic analyses in neuroblastoma cells confirm robust activation of these downstream signalling cascades following TrkC stimulation (maher2024atemporal(phospho)proteomic pages 1-2).  

## Inhibitors  
Clinically approved ATP-competitive pan-Trk inhibitors larotrectinib and entrectinib inhibit TrkC with nanomolar potency and are used to treat NTRK fusion-positive cancers (jiang2021developmentofsmallmolecule pages 1-6).  
Additional chemotypes such as EX429 and GNF-20 bind to either DFG-in or DFG-out conformations but exhibit limited isoform selectivity (bertrand2017crystalstructuresof pages 9-15).  
The 6KZC structure has been utilised to model the impact of kinase-domain mutations on the sensitivity to type I versus type II inhibitors (somwar2020ntrkkinasedomain pages 11-11).  
Next-generation inhibitors are in development to overcome acquired resistance mutations (jiang2021developmentofsmallmolecule pages 30-49).  

## Other Comments  
Chromosomal fusions such as ETV6-NTRK3 drive secretory breast carcinoma, infantile fibrosarcoma and congenital mesoblastic nephroma through constitutive kinase activation (jiang2021developmentofsmallmolecule pages 1-6).  
Somatic point mutations within the activation loop have been reported in colorectal, lung, breast and pancreatic cancers and may confer ligand-independent signalling (wood2006somaticmutationsof pages 4-7).  
Co-overexpression of TrkC and NT-3 transforms fibroblasts, underscoring the necessity for tight regulatory control (wai1999molecularcharacterizationof pages 28-33).  
Lack of isoform selectivity in current pan-Trk inhibitors raises concerns about central nervous system adverse effects (bertrand2017crystalstructuresof pages 9-15).

References

1. (bertrand2017crystalstructuresof pages 1-5): T. Bertrand. Crystal structures of neurotrophin receptors kinase domain. Vitamins and hormones, 104:1-18, 2017. URL: https://doi.org/10.1016/bs.vh.2016.10.001, doi:10.1016/bs.vh.2016.10.001. This article has 10 citations.

2. (bertrand2017crystalstructuresof pages 5-9): T. Bertrand. Crystal structures of neurotrophin receptors kinase domain. Vitamins and hormones, 104:1-18, 2017. URL: https://doi.org/10.1016/bs.vh.2016.10.001, doi:10.1016/bs.vh.2016.10.001. This article has 10 citations.

3. (jiang2021developmentofsmallmolecule pages 1-6): Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen, and Ouyang Liang. Development of small-molecule tropomyosin receptor kinase (trk) inhibitors for ntrk fusion cancers. Acta Pharmaceutica Sinica B, 11:355-372, Feb 2021. URL: https://doi.org/10.1016/j.apsb.2020.05.004, doi:10.1016/j.apsb.2020.05.004. This article has 113 citations and is from a peer-reviewed journal.

4. (jiang2021developmentofsmallmolecule pages 6-9): Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen, and Ouyang Liang. Development of small-molecule tropomyosin receptor kinase (trk) inhibitors for ntrk fusion cancers. Acta Pharmaceutica Sinica B, 11:355-372, Feb 2021. URL: https://doi.org/10.1016/j.apsb.2020.05.004, doi:10.1016/j.apsb.2020.05.004. This article has 113 citations and is from a peer-reviewed journal.

5. (wai1999molecularcharacterizationof pages 28-33): D. Wai. Molecular characterization of the etv6-ntrk3 fusion in congenital fibrosarcoma. Unknown journal, 1999. URL: https://doi.org/10.14288/1.0089499, doi:10.14288/1.0089499. This article has 1 citations.

6. (wood2006somaticmutationsof pages 4-7): Laura D. Wood, Eric S. Calhoun, Natalie Silliman, Janine Ptak, Steve Szabo, Steve M. Powell, Gregory J. Riggins, Tian-Li Wang, Hai Yan, Adi Gazdar, Scott E. Kern, Len Pennacchio, Kenneth W. Kinzler, Bert Vogelstein, and Victor E. Velculescu. Somatic mutations of gucy2f, epha3, and ntrk3 in human cancers. Human Mutation, Oct 2006. URL: https://doi.org/10.1002/humu.9452, doi:10.1002/humu.9452. This article has 114 citations and is from a domain leading peer-reviewed journal.

7. (barbacid1994thetrkfamily pages 1-2): Mariano Barbacid. The trk family of neurotrophin receptors. Journal of Neurobiology, 25:1386-1403, Nov 1994. URL: https://doi.org/10.1002/neu.480251107, doi:10.1002/neu.480251107. This article has 1741 citations.

8. (bertrand2012thecrystalstructures pages 2-5): T. Bertrand, M. Kothe, Jinyu Liu, A. Dupuy, A. Rak, P. Berne, S. Davis, T. Gladysheva, C. Valtre, J. Crenne, and M. Mathieu. The crystal structures of trka and trkb suggest key regions for achieving selective inhibition. Journal of molecular biology, 423 3:439-53, Oct 2012. URL: https://doi.org/10.1016/j.jmb.2012.08.002, doi:10.1016/j.jmb.2012.08.002. This article has 153 citations and is from a domain leading peer-reviewed journal.

9. (bertrand2017crystalstructuresof pages 15-18): T. Bertrand. Crystal structures of neurotrophin receptors kinase domain. Vitamins and hormones, 104:1-18, 2017. URL: https://doi.org/10.1016/bs.vh.2016.10.001, doi:10.1016/bs.vh.2016.10.001. This article has 10 citations.

10. (bertrand2017crystalstructuresof pages 9-15): T. Bertrand. Crystal structures of neurotrophin receptors kinase domain. Vitamins and hormones, 104:1-18, 2017. URL: https://doi.org/10.1016/bs.vh.2016.10.001, doi:10.1016/bs.vh.2016.10.001. This article has 10 citations.

11. (jiang2021developmentofsmallmolecule pages 30-49): Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen, and Ouyang Liang. Development of small-molecule tropomyosin receptor kinase (trk) inhibitors for ntrk fusion cancers. Acta Pharmaceutica Sinica B, 11:355-372, Feb 2021. URL: https://doi.org/10.1016/j.apsb.2020.05.004, doi:10.1016/j.apsb.2020.05.004. This article has 113 citations and is from a peer-reviewed journal.

12. (maher2024atemporal(phospho)proteomic pages 1-2): Stephanie Maher, Kieran Wynne, Vadim Zhernovkov, and Melinda Halasz. A temporal (phospho-)proteomic dataset of neurotrophic receptor tyrosine kinase signalling in neuroblastoma. Scientific Data, Oct 2024. URL: https://doi.org/10.1038/s41597-024-03965-y, doi:10.1038/s41597-024-03965-y. This article has 2 citations and is from a peer-reviewed journal.

13. (somwar2020ntrkkinasedomain pages 11-11): Romel Somwar, Nicolle E. Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Daniel Flynn, Marc Ladanyi, Alexander Drilon, Ujwal Shinde, and Monika A. Davare. Ntrk kinase domain mutations in cancer variably impact sensitivity to type i and type ii inhibitors. Communications Biology, Dec 2020. URL: https://doi.org/10.1038/s42003-020-01508-w, doi:10.1038/s42003-020-01508-w. This article has 60 citations and is from a peer-reviewed journal.

14. (tang2022negativeregulationof pages 1-2): Rong Tang, Wallace Y. Langdon, and Jian Zhang. Negative regulation of receptor tyrosine kinases by ubiquitination: key roles of the cbl family of e3 ubiquitin ligases. Frontiers in Endocrinology, Jul 2022. URL: https://doi.org/10.3389/fendo.2022.971162, doi:10.3389/fendo.2022.971162. This article has 29 citations and is from a peer-reviewed journal.

15. (wiesmann2001nervegrowthfactor pages 4-6): C. Wiesmann and A.M. de Vos. Nerve growth factor: structure and function. Cellular and Molecular Life Sciences, 58:748-759, May 2001. URL: https://doi.org/10.1007/pl00000898, doi:10.1007/pl00000898. This article has 317 citations and is from a domain leading peer-reviewed journal.

16. (cunningham1997autophosphorylationofactivation pages 11-12): Matthew E. Cunningham, Robert M. Stephens, David R. Kaplan, and Lloyd A. Greene. Autophosphorylation of activation loop tyrosines regulates signaling by the trk nerve growth factor receptor*. The Journal of Biological Chemistry, 272:10957-10967, Apr 1997. URL: https://doi.org/10.1074/jbc.272.16.10957, doi:10.1074/jbc.272.16.10957. This article has 211 citations.
